THERAPY DOSSIER · th-b2ae132e0c0f

BBT-015 (site-specifically PEGylated human G-CSF analogue PEG-A141C), BBT-007 (PEGylated murine GM-CSF analogue PEG-T3C), BBT-059 (PEGylated human IL-11 analogue PEG-*179C)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24276546 ↗2014Reported benefit

PEGylated G-CSF (BBT-015), GM-CSF (BBT-007), and IL-11 (BBT-059) analogs enhance survival and hematopoietic cell recovery in a mouse model of the hematopoietic syndrome of the acute radiation syndrome.

MouseRadiationC57BL/6Male and female (50/50)n = Survival group sizes not explicitly stated; studies powered…Subcutaneous0.1, 0.3 or 1.0 mg/kg depending on agent and scheduleFirst dose at 24 to 28 h (24 + 4 h) after total body irradiation

Model: Single dose uniform total body gamma irradiation (137Cs, 7.76-8.72 Gy, 0.62-1.02 Gy/min) producing the haematopoietic syndrome of the acute radiation syndrome (H-ARS)

All three PEGylated growth factors significantly improved 30-day survival. Nine doses of PEG-G-CSF gave 70 per cent (0.1 mg/kg) and 63 per cent (0.3 mg/kg) survival versus 28 per cent for vehicle (p<0.001), and a single dose gave 95 per cent (0.3 mg/kg) and 100 per cent (1.0 mg/kg) versus 65 per ce…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…